<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        41-370-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OLMETEC PLUS 40MG-12.5MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        87.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Olmetec Plus contains two active substances, olmesartan medoxomil<br />and hydrochlorothiazide, that are used to treat high blood pressure<br />)hypertension(: Olmesartan medoxomil is one of a group of medicines called<br />angiotensin 11-receptor antagonists. It lowers blood pressure by relaxing<br />the blood vessels. Hydrochlorothiazide is one of a group of medicines called<br />thiazide diuretics )&ldquo;water tablets&rdquo;(. It lowers blood pressure by helping the<br />body to get rid of extra fluid by making your kidneys produce more urine.<br />You will only be given Olmetec Plus if Olmetec )olmesartan medoxomil(<br />alone has not adequately controlled your blood pressure. When given<br />together, the two active substances in Olmetec Plus help to lower blood<br />pressure more than if either of them were given alone.<br />You may already be taking medicines to treat your high blood pressure, but<br />your doctor may want you to take Olmetec Plus to lower it more.<br />High blood pressure can be controlled with medicines such as Olmetec Plus<br />tablets. Your doctor has probably also recommended that you make some<br />changes in your lifestyle to help lower your blood pressure )for example<br />losing weight, giving up smoking, reducing the amount of alcohol you<br />drink and reducing the amount of salt in your diet(. Your doctor may also<br />have urged you to take regular exercise, such as walking or swimming. It is<br />important to follow this advice from your doctor<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Olmetec Plus</strong><br />&bull; If you are allergic )hypersensitive( to olmesartan medoxomil or to<br />hydrochlorothiazide, or to any of the other ingredients in the tablets )Section<br />6 contains a complete list( or to substances similar to hydrochlorothiazide<br />)sulfonamides(<br />&bull; If you are pregnant or may be pregnant<br />&bull; If you have diabetes or impaired kidney function and you are treated<br />with a blood pressure lowering medicine containing aliskiren<br />&bull; If you have severe kidney problems<br />&bull; If you suffer from low potassium, low sodium, high calcium or high uric acid<br />levels in the blood )with symptoms of gout or kidney stones( that do not get<br />better when treated<br />&bull; If you suffer from severe liver problems or yellowing of the skin and eyes<br />)jaundice( or problems with drainage of the bile from the gallbladder )biliary<br />obstruction e.g. gallstones(<br />&bull; If you think any of these apply to you, or you are unsure, do not take the<br />tablets. Talk to your doctor first and follow the advice given.<br /><strong>Take special care with Olmetec Plus</strong><br />Before you take the tablets, <strong>tell your doctor</strong> if you have any of the<br />following health problems:<br />&bull; Dual Blockade of the Renin-Angiotensin-aldosterone System )RAAS(:<br />Combination of Olmetec Plus with ACE inhibitors, or aliskiren may cause<br />increased risks of hyperkalemia, worsening of kidney function and<br />hypotension. Therefore, this combination should not be used, especially in<br />patients with kidney problems.<br />&bull; Mild to moderate kidney problems or if you have had a recent kidney<br />transplant<br />&bull; Liver diseases<br />&bull; Heart failure or problems with your heart valves or heart muscles<br />&bull; Vomiting )being sick( or diarrhoea which is severe or it goes on for several<br />days<br />&bull; Treatment with high doses of water tablets )diuretics( or if you are on a<br />low salt diet<br />&bull; Problems with your adrenal glands )e.g. primary aldosteronism(<br />&bull; Diabetes<br />&bull; Lupus erythematosus )an autoimmune disease(<br />&bull; Allergies or asthma.<br />Your doctor may want to see you more often and do some tests if you have<br />any of these conditions.<br />Olmetec Plus may cause a rise in blood fat levels and uric acid levels )the<br />cause of gout - painful swelling of the joints(. Your doctor will probably want<br />to do a blood test from time to time to check these.<br />It may change the levels of certain chemicals in your blood called electrolytes.<br />Your doctor will probably want to do a blood test from time to time to check<br />these. Signs of electrolyte changes are: thirst, dryness of the mouth, muscle<br />pain or cramps, tired muscles, low blood pressure )hypotension(, feeling<br />weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass<br />urine, a rapid heart rate. <strong>Tell your doctor if you notice these symptoms.</strong><br />As with any medicine which reduces blood pressure, an excessive drop in<br />blood pressure in patients with blood flow disturbances of the heart or brain<br />could lead to a heart attack or stroke. Your doctor will therefore check your<br />blood pressure carefully.<br />If you are due to have tests for parathyroid function, you should stop taking<br />Olmetec Plus before these tests are carried out.<br />If you are a sports person, this medicine could change the results of an antidope test to make it positive.<br />You must tell your doctor if you think that you are )or might become(<br />pregnant. Olmetec Plus is not recommended in early pregnancy, and must<br />not be taken if you are more than 3 months pregnant, as it may cause<br />serious harm to your baby if used at that stage )see pregnancy section(.<br />&bull; If you experience a decrease in vision or eye pain. These could be<br />symptoms of an increase of pressure in your eye and can happen within<br />hours to a week of taking Olmetec plus. This can lead to permanent vision<br />impairment, if not treated.<br />&bull; If you suffer from buildup of fluid between the choroid )the blood vessel<br />layer that nourishes the overlying retina( and the sclera, the white outer<br />covering of the eye.<br />&bull; If you had an allergic reaction to other high blood pressure medicines or<br />diuretics )a type of medicine also known as &quot;water tablets&quot;(, especially if<br />you suffer from asthma and allergies - if you have been sick )vomiting or<br />diarrhoea(.<br />&bull; If you had an allergic reaction to penicillin.<br /><strong>Taking other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken<br />any other medicines including medicines obtained without a prescription. In<br />particular, tell your doctor or pharmacist about any of the following:<br />&bull; If you have diabetes or impaired kidney function and you are treated<br />with a blood pressure lowering medicine containing aliskiren<br />&bull; Dual blockade )e.g. by adding ACE inhibitor to Olmetec Plus( should not be<br />used, especially in patients with Kidney problems.<br />&bull; Medicines which may raise the levels of potassium in your blood if used at<br />the same time as Olmetec Plus. These include:<br />&bull; Potassium supplements )as well as salt substitutes containing potassium(<br />&bull; Water tablets )diuretics(<br />&bull; Heparin )for thinning the blood(<br />&bull; Laxatives<br />&bull; Steroids<br />&bull; Adrenocorticotrophic hormone )ACTH(<br />&bull; Carbenoxolone )a medicine used to treat mouth and stomach ulcers(<br />&bull; Penicillin G sodium )also called benzylpenicillin sodium, an antibiotic(<br />&bull; Certain pain killers such as aspirin or salicylates<br />&bull; Lithium )a medicine used to treat mood swings and some types of<br />depression( used at the same time as Olmetec Plus may increase the toxicity<br />of lithium. If you have to take lithium, your doctor will measure your lithium<br />blood levels<br />&bull; Non-steroidal anti-inflammatory )NSAIDs( medicines )medicines used<br />to relieve pain, swelling and other symptoms of inflammation, including<br />arthritis( used at the same time as Olmetec Plus may increase the risk of<br />kidney failure and the effect of Olmetec Plus can be decreased by NSAIDs<br />&bull; Other blood pressure lowering medicines )anti-hypertensive(, as the<br />effect of Olmetec Plus can be increased<br />&bull; Sleeping tablets, sedatives and anti-depressant medicines, as using these<br />medicines together with Olmetec Plus may cause a sudden drop in blood<br />pressure when standing up<br />&bull; Certain medicines such as baclofen and tubocurarine, used to relax muscles<br />&bull; Amifostine and some other drugs used to treat cancers, such as<br />cyclophosphamide or methotrexate<br />&bull; Colestyramine and colestipol, medicines for lowering blood fat levels<br />&bull; Anticholinergic agents, such as Atropine and Biperiden<br />&bull; Drugs such as Thioridazine, Chlorpromazine, Levomepromazine,<br />Trifluoperazine, Cyamemazine, Sulpiride, Amisulpride, Pimozide, Suttopride,<br />Tiapride, Droperidol or Haloperidol, used to treat certain psychiatric<br />disorders<br />&bull; Certain medicines such as Quinidine, Hydroquinidine, Disopyramide,<br />Amiodarone, Sotalol or Digitalis, used to treat heart problems<br />&bull; Medicines such as Mizolastine, Pentamidine, Terfenadine, Dofetilide,<br />Ibutilide or Erythromycin injections, which may change the heart rhythm<br />&bull; Anti-diabetic medicines, such as Metformin, or Insulin, used to lower blood<br />sugar<br />&bull; Beta-blockers and Diazoxide, medicines used to treat high blood pressure<br />or low blood sugar, respectively, as Olmetec Plus can enhance their bloodsugar- increasing effect.<br />&bull; Methyldopa, a medicine used to treat high blood pressure<br />&bull; Medicines such as noradrenaline, used to increase blood pressure and slow<br />heart rate<br />&bull; Diphemanil, used to treat a slow heartbeat or reduce sweating<br />&bull; Medicines such as Probenecid, Sulfinpyrazone and Allopurinol, used to<br />treat gout<br />&bull; Calcium supplements<br />&bull; Amantadine, an anti-viral drug<br />&bull; Ciclosporin, a medicine used to stop rejection of organ transplants<br />&bull; Certain antibiotics called Tetracyclines or Sparfloxacin<br />&bull; Amphotericin, a medicine used to treat fungal infections<br />&bull; Certain antacids, used to treat too much stomach acid, such as aluminum<br />magnesium hydroxide, as the effect of Olmetec Plus can be slightly<br />decreased<br />&bull; Cisapride, used to increase food movement in the stomach and gut<br />&bull; Halofantrine, used for malaria.<br /><strong>Taking Olmetec Plus with food and drink</strong><br />Olmetec Plus can be taken with or without food.<br />Take care when drinking alcohol while you are taking Olmetec Plus, as some<br />people feel faint or dizzy. If this happens to you, do not drink any alcohol,<br />including wine, beer or alcopops.<br /><strong>Children and adolescents )under 18(</strong><br />Olmetec Plus is not recommended for children and adolescents under the<br />age of 18.<br /><strong>Black patients</strong><br />As with other similar drugs the blood pressure lowering effect of Olmetec<br />Plus is somewhat less in black patients.</p><p><strong>Pregnancy and breast-feeding</strong><br /><strong>Pregnancy</strong><br />Olmetec Plus should be avoided in pregnant or potentially pregnant women.<br />Administration should be discontinued immediately if the patient is found<br />to be pregnant during treatment.<br /><strong>Breastfeeding</strong><br />Tell your doctor if you are breast-feeding or about to start breastfeeding.<br />Olmetec Plus is not recommended for mothers who are breastfeeding, and<br />your doctor may choose another treatment for you if you wish to breastfeed.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Driving and using machines</strong><br />You may feel sleepy or dizzy while being treated for your high blood<br />pressure. If this happens, do not drive or use machines until the symptoms<br />wear off. Ask your doctor for advice.<br /><strong>Important Information about some of the Ingredients of Olmetec Plus<br />Lactose:</strong><br />This medicine contains lactose )a type of sugar(. If you have been told by<br />your doctor that you have an intolerance to some sugars, contact your<br />doctor before taking this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Olmetec Plus exactly as your doctor has told you. You should<br />check with your doctor or pharmacist if you are not sure.<br /><strong>The usual dose</strong> is one Olmetec Plus 20 mg/12.5 mg tablet a day. However,<br />if your blood pressure is not controlled, your doctor may decide to change<br />your dose to one Olmetec Plus 40 mg/12.5 mg or 40 mg/25 mg tablet a day.<br />Swallow the tablet with water.<br />If possible, you should take your dose at the same time each day, for<br />example at breakfast time.<br />It is important to continue to take Olmetec Plus until your doctor tells you<br />to stop.<br /><strong>If you take more Olmetec Plus than you should</strong><br />If you take more tablets than you should, or if a child accidentally swallows<br />one or more, go to your doctor or nearest accident and emergency<br />department immediately and take your medicine pack with you.<br /><strong>If you forget to take Olmetec Plus</strong><br />If you forget to take a dose, take your normal dose on the following day as<br />usual. Do not take any extra tablets to make up for the missed dose.<br /><strong>If you stop taking Olmetec Plus</strong><br />It is important to continue to take Olmetec Plus unless your doctor tells you<br />to stop. If you have any further questions on the use of this product, ask<br />your doctor or pharmacist<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Olmetec Plus can cause side effects, although not<br />everybody gets them. However, the following two side effects can be<br />serious:<br />&bull; Allergic reactions that may affect the whole body, with swelling of the<br />face, mouth and/or voice box )larynx( together with itching and rash may<br />occur rarely. <strong>If this happens, stop taking Olmetec Plus and contact your<br />doctor.</strong><br />&bull; Olmetec Plus can cause the blood pressure to fall too low in susceptible<br />individuals or as the result of an allergic reaction. Light-headedness or<br />fainting may occur uncommonly.<strong> If this happens, stop taking Olmetec<br />Plus, contact your doctor immediately and lie down flat.</strong><br />Olmetec Plus is a combination of two active substances and the following<br />information firstly gives the other side effects reported so far with the<br />combination Olmetec Plus )besides those already mentioned above( and,<br />secondly, those which are known about for the separate active substances.<br />To give you an idea of how many patients might get side effects, they have<br />been listed as common, uncommon, rare and very rare. These mean the<br />following:<br /><strong>Common </strong>affects less than 1 in 10 patients<br /><strong>Uncommon </strong>affects less than 1 in 100 patients<br /><strong>Rare </strong>affects less than 1 in 1,000 patients<br /><strong>Very rare </strong>affects less than 1 in 10,000 patients<br />Some changes in blood test results have also been seen uncommonly<br />and include: Reduced numbers of a type of blood cell, known as platelets<br />)thrombocytopenia(.<br /><strong>Rare side effects:</strong><br />Impaired kidney function, lack of energy.<br />Some changes in blood test results have also been seen rarely and include:<br />Increase in blood potassium.<br /><strong>Not known:</strong><br />Sprue-like enteropathy, you should contact your healthcare professional<br />right away if you experience severe diarrhea, diarrhea that does not go<br />away, or significant weight loss.&quot;<br /><strong>Hydrochlorothiazide:<br />Very common side effects:</strong><br />Changes in blood results including: Increase in blood fat and uric acid levels.<br /><strong>Common side effects:</strong><br />Feeling confused, abdominal pain, stomach upset, bloated feeling, diarrhoea,<br />nausea, vomiting, constipation, excretion of glucose into the urine. Some<br />changes in blood results have also been seen and include:<br />Increase in blood creatinine, urea, calcium and sugar levels, decrease in<br />blood chloride, potassium, magnesium and sodium levels. Increase of serum<br />amylase )hyperamylasaemia(.<br /><strong>Uncommon side effects:</strong><br />Decreased or loss of appetite, severe difficulty breathing, anaphylactic skin<br />reactions )hypersensitivity reactions(, worsening of pre-existing myopia,<br />erythema, skin reactions to light itching, purplish spots or patches on the<br />skin due to small haemorrhages )purpura(, skin lumps )wheals(.<br /><strong>Rare side effects:</strong><br />Swollen and sore salivary glands, decreased number of white blood cells,<br />decreased number of blood platelets, anaemia, bone marrow damage ,<br />restlessness, feeling &lsquo;down&rsquo; or depressed, problems sleeping, feeling uninto rested )apathy(, tingling and numbness, fits )convulsions(, objects<br />you look at appearing yellow, blurred vision, dry eyes, irregular heartbeat,<br />inflammation of the blood vessels, blood clots )thrombosis or embolism(,<br />inflammation of the lung, fluid accumulation in the lungs, inflammation<br />of the pancreas, jaundice , infection in the gall bladder, symptoms of<br />lupus erythematosus such as rash, joint pains and cold hands and fingers,<br />allergic skin reactions , peeling and blistering of the skin, non-infectious<br />inflammation of the kidney )interstitial nephritis(, fever, muscle weakness<br />)sometimes causing impaired movement(.<br /><strong>Very rare side effects:</strong><br />Electrolyte disturbance leading to an abnormally depleted level of chloride<br />in the blood )hypochloraemic alkalosis(, blockage in the gut )paralytic ileus(.<br />If any of the side effects gets serious, or if you notice any side effects not<br />listed in this leaflet, please tell your doctor or pharmacist.<br /><strong>Not known:</strong><br />Choroidal effusion )an abnormal accumulation of fluid in the suprachoroidal<br />space(.<br />If you experience yellowing of the whites of the eyes, dark urine, itching of<br />the skin, even if you started therapy with Olmetec Plus long ago, contact<br />your doctor immediately who will evaluate your symptoms and decide on<br />how to continue your blood pressure medication.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C<br />Do not use Olmetec Plus after the expiry date )&ldquo;EXP&rdquo;( which is stated on<br />the box and on the blister strip. The expiry date refers to the last day of<br />that month. Medicines should not be disposed via wastewater or household<br />waste. Ask your pharmacist how to dispose of medicines no longer required.<br />These measures will help to protect the environment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substances are Olmesartan medoxomil and Hydrochlorothiazide.<br />&bull; The other ingredients are Microcrystalline cellulose, lactose monohydrate*,<br />Low substitute Hydroxy propyl cellulose, Hydroxy propyl cellulose,<br />magnesium stearate and Opadry<br />*See &lsquo;Important Information about some of the Ingredients of Olmetec Plus&rsquo;<br />section above<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                − OLMETEC PLUS 20 /12.5 mg are light orange, circular, film-coated tablets
with characteristic odor, and Coded by SJ 225 on one side.
− OLMETEC PLUS 40 /12.5 mg are light orange, biconvex oblong, film-coated
tablets with characteristic odor, and Coded by SJ 227 on one side
− OLMETEC PLUS 40 /25 mg are pinkish, biconvex oblong, film-coated
tablets with characteristic odor, and Coded by SJ 231 on one side
− All Packs contain 28 film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Saudi Arabia<br />Under license from<br />Daiichi Sankyo Co. Ltd.<br />Tokyo-Japan</p><p><br /><strong>To report any side effect)s(:<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; United Arab Emirates</strong><br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email : pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai - UAE<br /><strong>&bull; Other GCC States / other countries:</strong><br />- Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتــوي أولميتــك بلــس علــى اثنيــن مــن المــواد الفعاًلــة وهمــاً: أولميســاًرتاًن ميدوكســوميل،<br />وهيدروكلوروثياًزيــد، حيــث يتــم اســتخدامهاً لــعلاج ارتفــاًع ضـــغط الــدم<br />أولميســاًرتاًن ميدوكســوميل هــو أحــد الأدويــة مــن مجموعــة مناًهضــاًت مســتقبلات هرمــون<br />الأنجيوتنســينُ .2 يخفــض أولميتــك بلــس مــن ضــغـط الــدم عــن طريــق إرخــاًءً الأوعيــة الدمويــة<br />ُيعــد هيدروكلوروثياًزيــد هــو أحــد الأدويــة مــن مجموعــة مــدرات البــول الثياًزيديــة (أقراص المــاًءً،) وهــو<br />يخفـض مـن ضغط الـدم عـن طريـق مسـاًعدة الجسـم فـي التخلـص مـن السـوائل الزائـدة مـن خلال جعـل<br />كليتيـك تنتجـاًن المزيـد مـن البـول. سـيتم إعطـاًؤك أولميتـك بلـس فقـط إذا كاًن أولميتـك ( أولميسـاًرتاًن<br />ميدوكســوميل) لا يمكنــه التحكــم وحــده فــي ضـــغط الــدم لديــك بشــكل كاًف. عنــد إعطــاًءًك كلاهمــاً<br />ً معـاً، ستسـاًعد الماًدتـاًن الفعاًلتـاًن الموجودتـاًن فـي أولميتـك بلـس فـي خفـض ضـغـط الـدم بشـكل أكبـر<br />ممـاً إذا تـم إعطـاًءً أي منهمـاً مسـتقلا<br />قــد تكــون باًلفعــل تتنــاًول أدويــة لــعلاج ارتفــاًع ضــغـط الــدم لديــك، ومــع ذلــك قــد يطلــب منــك طبيبــك<br />تنــاًول أولميتــك بلــس لخفــض الضـــط بشــكل أكبــر<br />يمكـن التحكـم فـي ضــط الـدم المرتفـع باًسـتخدام أدويـة مثـل أقراص أولميتـك بلـس. قـد يكـون طبيبـك<br />قـد أوصـاًك أيضـاً بـإجراءً بعـض التـغيـيرات فـي أسـلوب حياًتـك للمسـاًعدة فـي خفـض ضــغط الـدم لديـك<br />(علــى سبيــل المثــاًل: إنقــاًص الــوزن، والإقلاع عــن التدخيــن، وتقليــل كميــة الكحوليــاًت التــي تتناًولهــاً،<br />وتقليــل كميــة الملــح فــي طعاًمــك.) قــد يكــون طبيبــك قــد حثــك أيضــاً علــى مماًرســة التماًريــن بشــكل<br />منتــظم، مثـل: المشـي أو السـباًحة. مـن المهـم اتباًعـك لنصاًئـح الطبيـب<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول أولميتك بلس في الحالات الآتية:</strong><br />&bull; إذا كنـت تعاًنـي مـن الحساًسـية (فرط الحساًسـية) تجـاًه أولميسـاًرتاًن ميدوكسـوميل أو هيدروكلوروثياًزيد<br />أو تجـاًه أي مـن المكونـاًت الأخـرى الموجـودة فـي الأقراص (يحتـوي قسـم &quot; &quot;6علـى قاًئمـة كاًملـة بهـاً)<br />أو تجـاًه مـواد مشـاًبهة للهيدروكلوروثياًزيـد (السـفوناًميدات &quot;مضـاًد حيوي)&quot;<br />&bull; إذا كنت حاًملا أو قد تكونين حاًملا.<br />&bull; اذا كنـت تعاًنـي مـن مـرض السـكري أو خلـل فـي وظاًئـف الكلـى وتتلقـى علا ًجـاً يحتـوي علـى عقـاًر<br />لخفـض ضــغط الـدم يحتـوي علـى اليسـكيرين<br />&bull; إذا كنت تعاًني من مشاًكل باًلكلى.<br />&bull; إذا كنــت تعاًنــي مــن انخفــاًض مســتوياًت البوتاًســيوم، أو الصوديــوم، أو ارتفــاًع مســتوياًت الكاًلســيوم،<br />أو حمـض اليوريـك فـي الـدم (مـع أعراض النقـرس أو حصـوات الكلـى) التـي لا تتحسـن عنـد علاجهـاً<br />&bull; إذا كنـت تعاًنـي مـن مشـاًكل شـديدة باًلكبـد أو اصـفرار البشـرة والعينيـن (اليرقـاًن) أو مشـاًكل مرتبطـة<br />بتصريـف العصـاًرة الصفراويـة مـن الـمرارة (انسـداد الجهـاًز الصـفراوي؛ مثـل حصـى الـمرارة)<br />ً إذا كنـت تعتقـد أن أيـاً ممـاً سـبق ينطبـق عليـك، أو لـم تكـن متأكـد ًا مـن ذلـك، فلا تتنـاًول الأقراص. تحـدث<br />إلـى طبيبـك أولا، ثـم اتبـع النصيحـة التـي سـيعطيهاً لـك<br /><strong>َتوخ حذر ًا خاصا مع أولميتك بلس</strong><br />قبل أن تتناًول الأقراص أخبر طبيبك إذا كنت تعاًني من أي من المشاًكل الصحية التاًلية:<br />&bull; نـاًم حاًصرات الرينين أنجيوتنسين ألدوستيرون (:)RAAS<br />اسـتعماًل عقـاًر أولميتـك بلـس مـع مثبطـاًت الأنزيـم المحـول للأنجيوتنسـين، أو عقـاًر اليسـكاًرين قـد يسـبب<br />مخاًطـر إرتـفاًع نسـبة البوتاًسـيوم باًلـدم، وتدهـور وظاًئـف الكلـى وانخفـاًض ضــغط الـدم. ولذلـك، يجـب ألا<br />تسـتعمل هـذه العقاًقيـر معـاً، خصوصـاً فـي المرضـى الذيـن يعاًنـون مـن مشـاًكل فـي الكلـى<br />&bull; مشاًكل خفيفة إلى معتدلة باًلكلى، أو إذا كنت قد خضعت مؤخر ًا إلى عملية زرع ُكلى.<br />&bull; أمراض الكبد.<br />&bull; هبوط القلب أو مشاًكل في صماًماًت أوعضلة القلب.<br />&bull; قيءً (الشعور باًلإعياًءً،) أو إسهاًل شديد أو مستمر لعدة أياًم.<br />&bull; تنــاًول علاج بجرعــاًت مرتفعــة مــن أقراض المــاًءً (مــدرات البــول) أو إذا كنــت تتبــع نـظامــاً ً غذائيــاً قليــل<br />الملــح<br />&bull; مشاًكل في الـغدد الكظـرية (على سبيل المثاًل: الألدوستيرونية الأولية.)<br />&bull; مرض السكري.<br />&bull; ذئبة حمراءً (حماًمية) (أحد أمراض المناًعة الذاتية.)<br />&bull; حساًسية أو ربو.<br />قـد يطلـب طبيبـك رؤيتـك بشـكل أكثـر تـكرار ًا، وإجراءً بعـض الاختبـاًرات لـك إذا كنـت تعاًنـي مـن أي مـن<br />هـذه الحـاًلات. قـد يـؤدي أولميتـك بلـس إلـى ارتفـاًع فـي مسـتوياًت دهـون وحمـض اليوريـك فـي الـدم<br />(الإصاًبـة باًلنقـرس- تـورم مؤلـم فـي المفاًصـل.) قـد يطلـب منـك طبيبـك إجراءً اختبـاًر باًلـدم مـن حيـن إلـى<br />آخـر للتحقـق مـن ذلـك<br />قـد ُيـغيـر أولميتـك بلـس مـن مسـتوياًت بعـض المـواد الكيمياًئيـة فـي الـدم والتـي تسـمى باًلإلكتروليتـاًت<br />(الكهــاًرل.) قــد يطلــب منــك طبيبــك إجراءً اختبــاًر باًلــدم مــن حيــن إلــى آخــر؛ للتحقــق مــن ذلــك. تكــون<br />العلامـاًت علـى حـدوث تــغيرات فـي الإلكتروليتـاًت هـي: عطـش، جفـاًف الفـم، ألـم أو تقلـص باًلعـضلات،<br />إجهـاًد العـضلات، انخفـاًض ضــغط الـدم، شعور باًلضعـف، باًلكسـل، باًلتعـب، باًلنعـاًس أو التملمـل، غثيـاًن،<br />قـيءً، انخفـاًض فـي الحاًجـة إلـى التبـول، زيـاًدة معـدل ضربـاًت القلـب<br /><strong>أخبر طبيبك إذا لاحظت ظهور هذه الأعراض.</strong><br />كمـاً هـو الحـاًل مـع أي دواءً خاًفـض لضــغط الـدم، قـد يـؤدي الانخفـاًض المفـرط فـي ضغــط الـدم لـدى<br />المرضـى الذيـن يعاًنـون مـن اضطرابـاًت بتدفـق الـدم باًلقلـب أو باًلمـخ إلـى نوبـة قلبيـة، أو سـكتة دماًغيـة؛<br />لــذا يجــب أن يقــوم طبيبــك بفحــص ضــغـط الــدم لديــك بعناًيــة. إذا كاًن مــن المــقرر خضوعــك لاختبــاًرات<br />لوظاًئـف الـغـدة الدرقيـة، فيجـب التوقـف عـن تنـاًول أولميتـك بلـس قبـل القيـاًم بمثـل هـذه الاختبـاًرات<br />إذا كنــت ـ ًشخصاً رياًضيــاً، فمــن الممكــن أن يـغيــر هــذا الــدواءً مــن نتاًئــج اختبــاًر الكشــف عــن المنشــطاًت<br />وجعلهــاً إيجاًبيــة. يجــب إبلاغ طبيبــك إذا كنــت تعتقديــن أنــك حاًمــل (أو قــد تصبحيــن حــاًملا.) لا يوصــى<br />بتنـاًول أولميتـك بلـس فـي المراحـل المبكـرة مـن الحمـل، ويجـب ألا ُيتنـاًول إذا تجـاًوز حملـك الشـهر الثاًلـث،<br />حيـث قـد يلحـق بطفلـك ضرر خطيـر إذا تـم اسـتخدامه فـي هـذه المرحلـة (انــظري قسـم&quot;الحمل)&quot;<br />- إذا كنـت قـد تعرضـت لانخفـاًض فـي الرؤيـة أو ألـم باًلعيـن. يمكـن أن تكـون هـذه أعراض لزيـاًدة ضــغط<br />العيـن، وقـد تحـدث فـي غضـون سـاًعاًت إلـى أسـاًبيع مـن تنـاًول عقـاًر أولميتيـك بلـس. يمكـن أن ُيـؤدي<br />ذلـك إلـى ضعـف دائـم باًلإبصـاًر، إذا لـم يتـم علاجـه<br />- إذا كنـت تعاًنـي مـن تراكـم للسـوائل بيـن المشـيمية (الطبقـة التـي تحتـوي علـى الأوعيـة الدمويـة التـي<br />تــغذي الشـبكية ) والصلبـة، الـغطـاًءً الخاًرجـي الأبيـض للعيـن<br />- إذا ُأ ِصبـت بتفـاًعلات حساًسـية تجـاًه أدويـة علاج ارتفـاًع ضــغط الـدم الأخـرى أو ُمـدرات البـول (نـوع مـن<br />الأدويـة و ُيعـرف أيضـاً باًسـم: &quot;أقراص المـاًءً،)&quot; لا سـيماً إذا كنـت ُتعاًنـي مـن الربـو والحساًسـية - إذا كنـت<br />ُمصاًبـاً بإعيـاًءً (قـيءً أو إسـهاًل)<br />- إذا ُأ ِصبت بتفاًعلات حساًسية تجاًه البنيسيللين<br /><strong>تناول أدوية أخرى</strong><br />يرجـى إبلاغ الطبيـب أو الصيدلـي الخـاًص بـك إذا كنـت تتنـاًول أو تناًولـت مـؤخر ًا أيـة أدويـة أخـرى، بمـاً<br />فيهـاً الأدويـة التـي يتـم الحصـول عليهـاً دون وصفـة طبيـة<br />على وجه الخصوص، أخبر الطبيب أو الصيدلي الخاًص بك عن أي مماً يلي:<br />&bull; إذا كنـت تعاًنـي مـن مـرض السـكري أو خلـل فـي وظاًئـف الكلـى وتتلقـى علا ًجـاً يحتـوي علـى عقـاًر<br />لخفـض ضـغـط الـدم يحتـوي علـى اليسـكيرين<br />&bull; يجــب عــدم اســتعماًل حــاًصرات رينيــن انجيوتنســين المــزدوج (مثــاًلا مــع مثبطــاًت الأنزيــم المحــول<br />للأنجيوتنســين لــدواءً أولميتــك بلــس،) وخاًصــة فــي المرضــى الذيــن يعاًنــون مــن مشــاًكل فــي الكلــى<br />&bull; أدويـة قـد تـؤدي إلـى ارتفـاًع مسـتوياًت البوتاًسـيوم فـي الـدم إذا تـم اسـتخدامهاً باًلتزامـن مـع أولميتـك<br />بلـس. وتشـمل هـذه الأدويـة الآتـي<br />&bull; المكــملات الـذائيــة التــي تحتــوي علــى البوتاًســيوم (وكذلــك بدائــل الملــح التــي تحتــوي علــى<br />البوتاًســيوم)<br />&bull; أقراص الماًءً (مدرات البول.)<br />&bull; هيباًرين (لإحداث سيولة في الدم.)<br />&bull; المليناًت.<br />&bull; الستيرويدات.<br />&bull; الهرمون الموجه لقشرة الغـدة الكـظرية (.)ACTH<br />&bull; كربينوكسولون (دواءً ُيستخدم لعلاج قرح الفم والمعدة.)<br />&bull; بنسيلين الصوديوم&quot;جي&quot; : ( ُيسمى أيضاً بنزيل بنسيلين الصوديوم، وهو مضاًد حيوي.)<br />&bull; بعض المسكناًت مثل الأسبيرين أو مركباًت الساًليسيلات.<br />&bull; الليثيـوم: (دواءً ُيسـتخدم لـعلاج التقلبـاًت المزاجيـة وبعـض أنـواع الإكتئـاًب،) حيـث قـد يزيـد اسـتخدامه<br />فـي نفـس الوقـت مـع أولميتـك بلـس مـن سـمية الليثيـوم. إذا كاًن يجـب عليـك تنـاًول الليثيـوم، فسـيقوم<br />طبيبـك بقيـاًس مسـتوياًت الليثيـوم لديـك فـي الـدم<br />&bull; مضـاًدات الالتهـاًب غيـر السـتيرويدية &quot;( &quot;NSAIDsأدويـة تسـتخدم لتخفيـف الألـم والتـورم وأعراض أخـرى<br />للالتهـاًب مـن بينهـاً التهـاًب المفاًصـل،) حيـث إن اسـتخدامهاً فـي نفـس الوقـت مـع أولميتـك بلـس قـد<br />يزيــد مــن خطــورة الفشــل الكلــوي، وقــد يقــل تأثيــر أولميتــك بلــس عنــد تناًولــه مــع مضــاًدات الالتهــاًب<br />الســتيرويدية<br />&bull; أدويـة أخـرى خاًفضـة لضـغـط الـدم (مضـاًدة لارتفـاًع ضـغـط الـدم)؛ لأن ذلـك قـد يزيـد مـن تأثيـر أولميتـك<br />بلس<br />&bull; أقراص النـوم، المهدئـاًت والأدويـة المضـاًدة للاكتئـاًب؛ لأن اسـتخدام هـذه الأدويـة بمصاًحبـة أولميتـك<br />بلـس قـد يحـدث هبوطـاً فـي ضـغـط الـدم عنـد النهـوض<br />&bull; بعض الأدوية مثل باًكلوفين وتوبوكورارين- يستخدماًن لإرخاًءً العضلات.<br />&bull; أميفوســتين وبعــض الأدويــة الأخــرى التــي تســتخدم لــعلاج الســرطاًناًت، مثــل سيكلوفســفاًميد أو<br />ميثوتريكســاًت<br />&bull; كوليسترامين وكوليستيبول، أدوية خاًفضة لمستوياًت الدهون في الدم.<br />&bull; مضاًدات الكولينياًت، مثل: أتروبين وبيبيريدين.<br />&bull; أدويــة مثــل: ثيوريدازيــن، كلوربروماًزيــن، ليفوميبروماًزيــن، تريفلوبيرازيــن، ســياًميماًزين، ســولبيريد،<br />أميسـولبيريد، بيموزيـد، سـلتوبريد، تياًبريـد، دروبيريـدول أو هاًلوبيريـدول، حيـث يتـم اسـتخدامهاً لـعلاج بعـض<br />الإضطرابــاًت النفســية<br />&bull; بعـض الأدويـة مثـل: كينيديـن، هيدروكينيديـن، ديسـوبيراميد، أميـودارون، سـوتاًلول أو ديجيتاًليـس، حيـث<br />يتـم اسـتخدامهاً لـعلاج مشـاًكل القلـب<br />&bull; أدويــة مثــل: ميزولاســتين، بنتاًميديــن، تيرفيناًديــن، دوفيتيليــد، حقــن إيبوتيليــد أو إريثروميســين &ndash; قــد تـغيــر<br />مـن انتــظاًم ضربـاًت القلـب<br />&bull; الأدويـة المضـاًدة لمـرض السـكري، مثـل مينفورميـن، أو إنسـولين، حيـث يتـم اسـتخدامهاً لخفـض سـكر<br />الـدم<br />&bull; حـاًصرات بيتـاً ودياًزوكسـيد، أدويـة يتـم اسـتخدامهاً لـعلاج ارتفـاًع ضــغط الـدم، أو انخفـاًض سـكر الـدم،<br />علـى التوالـي؛ لأن أولميتـك بلـس يمكنـه تعزيـز تأثيرهـاً علـى رفـع سـكر الـدم<br />&bull; ميثيل دوباً، دواءً يستخدم لعلاج ارتفاًع ضـغط الدم.<br />&bull; أدوية مثل: نورأدريناًلين، تستخدم لزياًدة ضـغط الدم ومعدل ضرباًت القلب البطيءً.<br />&bull; ديفيماًنيل: يستخدم لعلاج بطءً ضرباًت القلب أو تقليل التعرق.<br />&bull; أدوية مثل: بروبينسيد، سلفينباًيرازون (سولفين بيرازون) وألوبيورينول، تستخدم لعلاج النقرس.<br />&bull; المكملات الـذائية التي تحتوي على الكاًلسيوم.<br />&bull; أماًنتاًدين، مضاًد للفيروساًت.<br />&bull; سيكلوسبورينن دواءً يستخدم لوقف رفض الجسم للأعضاًءً المزروعة.<br />&bull; بعض المضاًدات الحيوية التي تسمى تتراسيكليناًت أو سباًرفلوكساًسين.<br />&bull; أمفوتيريسين، دواءً يستخدم لعلاج العدوى الفطرية.<br />&bull; بعــض مضــاًدات الحموضــة، تســتخدم لــعلاج الكميــاًت الزائــدة مــن الأحمــاًض فــي المعــدة مثــل:<br />هيدروكســيد الالومينيــوم والماًغنســيوم؛ لإمكاًنيــة انخفــاًض تأثيــر أولميتــك بلــس قليلا<br />&bull; سيساًبريد، يستخدم لزياًدة حركة الطعاًم في المعدة والأمعاًءً.<br />&bull; هاًلوفاًنترين يستخدم لعلاج الملارياً.<br /><strong>تناول أولميتك بلس مع الطعام والشراب</strong><br />يمكن تناًول أولميتك بلس مع الطعاًم أو بدونه.<br />تــوخ الحــذر عنــد تنــاًول الكحوليــاًت أثنــاًءً تنــاًول أولميتــك بلــس، حيــث قــد يشــعر بعــض الأشخاًص بإغمــاًءً<br />أو دوخــة<br />إذا حدث لك ذلك، فلا تتناًول أية كحولياًت، بماً في ذلك النبيذ أو البيرة أو المشروباًت الروحية.<br /><strong>الأطفال والمراهقين (أقل من 18سنة)</strong><br />لا يوصى باًستخدام أولميتك بلس للأطفاًل والمراهقين أقل من 18سنة.<br /><strong>المرضى ذوي البشرة السمراء</strong><br />كمـاً هـو الحـاًل مـع أدويـة أخـرى يكـون تأثيـر أولميتـك بلـس الخاًفـض لضــط الـدم أقـل إلـى حـد مـاً فـي<br />المرضـى ذوي البشـرة السـمراءً<br /><strong>الحمل والرضاعة</strong><br /><strong>الحمل</strong><br />يجــب تجنــب اســتخدام أولميتيــك بلــس فــي النســاًءً الحوامــل أو اللواتــي قــد يكــن حوامــل. يجــب وقــف<br />الــعلاج علــى الفــور إذا تبيــن أن المريضــة حاًمــل خلال فتــرة الــعلاج<br /><strong>الرضاعة الطبيعية</strong><br />أخبـري طبيبـك إذا كنـت ً ترضعيـن طفلـك طبيعيـاً أو إذا كنتـي علـى وشك البـدءً فـي الرضاًعـة الطبيعيـة.<br />لا يوصــى باًســتخدام الأمهــاًت المرضعــاًت لأولميتــك بلــس، وقــد يختــاًر لــك ً طبيبــك علاجــاً آخــر إذا كنــت<br />ترغبيـن فـي مماًرسـة الرضاًعـة الطبيعيـة<br />استشيري الطبيب أو الصيدلي الخاًص بك قبل تناًول أي دواءً.<br /><strong>القيادة واستخدام الآلات</strong><br />قـد تشـعر بنعـاًس أو دوخـة أثنـاًءً علاجـك مـن ارتفـاًع ضــغط الـدم لديـك. إذا حـدث لـك ذلـك، فلا تمـاًرس<br />القيــاًدة ولا تســتخدم الآلات حتــى تزول الأعراض. استشــر طبيبــك<br /><strong>معلومات هامة عن بعض مكونات أولميتك بلس<br />اللاكتوز:</strong><br />يحتـوي هـذا الـدواءً علـى سـكر ال &quot;لاكتـوز.&quot; إذا كاًن قـد تـم إبلاغـك مـن قبـل طبيبـك بأنـك تعاًنـي مـن<br />عـدم تحمـل لبعـض أنـواع السـكرياًت، فاًتصـل بطبيبـك قبـل تنـاًول هـذا الـدواءً<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تنـاًول دائمـاً أولميتـك بلـس باًلضبـط كمـاً أخبـرك طبيبـك. إذا لـم تكـن متأكـد ًا مـن كيفيـة التنـاًول، فيجـب<br />عليـك مراجعـة الطبيـب أو الصيدلـي الخـاًص بـك<br /><strong>الجرعـة المعتـادة</strong>: قـرص واحـد فـي اليـوم مـن أولميتـك بلـس 20ملـج/ 12.5ملـج. ومـع ذلـك، إذا لـم تتـم<br />السـيطرة علـى ضغــط الـدم لديـك، فقـد يـقرر طبيبـك تـغييـر جرعتـك مـن أولميتـك بلـس إلـى قـرص واحـد<br />فـي اليـوم 40ملـج/ 12.5ملـج أو 40ملـج/ 25ملـج<br />ابتلع القرص مع كمية من الماًءً.<br />إن أمكن، يجب تناًول جرعتك في نفس الوقت من كل يوم، على سبيل المثاًل، في وقت الإفطاًر.<br />من المهم أن تستمر في تناًول أولميتك بلس ماً لم يخبرك طبيبك باًلتوقف.<br /><strong>إذا تناولت كمية من أولميتك بلس أكثر مما يجب</strong><br />إذا تناًولــت أقراصــاً أكثــر ممــاً ً يجــب، أو إذا ابتلــع طفــل قرصــاً منهــاً أو أكثــر بطريــق الخطــأ، فتوجــه إلــى<br />طبيبــك أو إلــى أقــرب قســم للطــوارئ علــى الفــور، واصطحــب معــك عبــوة الــدواءً<br /><strong>إذا نسيت تناول أولميتك بلس</strong><br />إذا نسـيت تنـاًول جرعـة، فتنـاًول جرعتـك العاًديـة فـي اليـوم التاًلـي كاًلمعتـاًد. لا تتنـاًول أيـة أقراص إضاًفيـة<br />لتعويـض الجرعـة التي نسـيتهاً<br /><strong>إذا توقفت عن تناول أولميتك بلس</strong><br />من المهم أن تستمر في تناًول أولميتك بلس ماً لم يخبرك طبيبك باًلتوقف.<br />إذا كان لديـك أيـة أسـئلة أخـرى حـول اسـتخدام هـذا الـدواء، فاستشـر الطبيـب أو الصيدلـي الخـاص<br />بك<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثـل جميـع الأدويـة، يمكـن أن يسـبب أولميتـك بلـس أعراض جاًنبيـة، لكنهـاً لا تحـدث للجميـع. ومـع ذلـك،<br />يمكـن أن يكـون الأثران الجاًنبيـاًن التاًليـاًن خطيريـن<br />&bull; تفـاًعلات حساًسـية قـد تؤثـر علـى الجسـم كلـه، مـع تـورم فـي الوجـه، الفـم و/أو الحنجـرة مـع حكـة،<br />وطفــح جلــدي أثنــاًءً الــعلاج باًســتخدام أولميتــك بلــس. <strong>إذا حــدث ذلــك فتوقــف عــن أولميتــك بلــس،<br />واتصــل بطبيبــك علــى الفــور.</strong><br />&bull; ً قــد يحــدث أولميتــك بلــس هبوطــاًشـديد َا فــي ضـــغط الــدم لــدى الأفراد المعرضيــن لذلــك أو نتيجــة<br />لتفاًعــل حساًســية قــد تحــدث دوخــة أو إغمــاًءً بشــكل غيــر شاًئع. <strong>إذا حــدث ذلــك فتوقــف عــن تنــاول<br />أولميتــك بلــس، اتصــل بطبيبــك علــى الفــور وتمــدد فــي وضــع الاســتلقاء.</strong><br />ً يعــد أولميتــك بلــس مزيجــاً مــن اثنيــن مــن المــواد الفعاًلــة، المعلومــاًت التاًليــة توضــح لــك أو ًلا الأعراض<br />الجاًنبيـة الأخـرى التـي تـم الإبلاغ عنهـاً حتـى الآن مـع أولميتـك بلـس (بجاًنـب تلـك المذكـورة أعلاه) وثاً ً نيـاً،<br />الأعراض الجاًنبيـة المعروفـة لـكلا مـن تلـك المـواًد الفعاًلـة علـى حـده<br />لنعطيــك فكــرة عــن عــدد المرضــى الذيــن قــد يعاًنــون مــن الأعراض الجاًنبيــة، تــم إدراج الأعراض الجاًنبيــة<br />علــى هيئــة أعراض جاًنبيــة شاًئعة، وغيــر شاًئعة، نــاًدرة، نــاًدرة جــد ًا. وهــي تعنــي مــاً يلــي<br />.<strong>شاًئعة </strong>تؤثر على أقل من ـخص واحد بين كل 10أـخاًص<br /><strong>غير شاًئعة </strong>تؤثر على أقل من ـخص واحد بين كل 100ـخص<br /><strong>ناًدرة </strong>تؤثر على أقل من ـخص واحد بين كل 1000ـخص.<br /><strong>ناًدرة جد ًا</strong> تؤثر على أقل من ـخص واحد بين كل 10000ـخص.<br />ً تمت أيضاً ملاحـظة بعض التـغييرات في نتاًئج اختباًرات الدم بشكل غير شاًئع وتتضمن ماً يلي:<br />انخفاًض أعداد نوع من خلاياً الدم، يعرف باًلصفاًئح الدموية (قلة الصفاًئح الدموية.)<br /><strong>الأعراض الجانبية النادرة:</strong><br />قصور في وظاًئف الكلى، فقدان الطاًقة.<br />كماً تمت ملاحـظة بعض التـغييرات في نتاًئج فحوصاًت الدم بشكل ناًدر تتضمن ماً يلي:<br />ارتفاًعاً في مستوياًت البوتاًسيوم في الدم.<br /><strong>غير معروف:</strong><br />ذرب الأمعـاًءً: إسـهاًل شديد بسـبب مـرض فـي الأمعـاًءً وبسـبب فقـدان الـوزن وينبــغي الاتصـاًل باًلطبيـب<br />عنـد الشـعور بهـذه الأعراض<br /><strong>هيدروكلوروثيازيد:</strong><br /><strong>الأعراض الجانبية الشائعة جد ًا:</strong><br />تـغيرات في نتاًئج اختباًرات الدم وتشمل: ارتفاًع مستوياًت ضـغط الدم.<br /><strong>الأعراض الجانبية الشائعة:</strong><br />شعور باًلارتبــاًك، ألــم فــي البطــن، اضــطراب المعــدة، شعور باًلانتفــاًخ، إســهاًل، غثيــاًن، قــيءً، إمســاًك،<br />مرور الجلوكــوز إلــى البــول<br />كماً تمت ملاحـظة بعض التـغييرات في نتاًئج فحوصاًت الدم وتتضمن ماً يلي:<br />ارتفــاًع مســتوياًت الكرياًتينيــن واليوريــاً والكاًلســيوم والســر فــي الــدم، انخفــاًض مســتوياًت الكلوريــد<br />والبوتاًســيوم والماًغنيســيوم والصوديــوم فــي الــدم، ارتفــاًع مســتوياًت إنزيــم أمــيلاز فــي الــدوم (فــرط<br />أمــيلاز الــدم)<br /><strong>الأعراض الجانبية غير الشائعة:</strong><br />انخفــاًض أو فقــدان الشــهية، صعوبــة شديدة فــي التنفــس، تفــاًعلات تاًقيــة باًلجلــد (تفــاًعلات فــرط<br />الحساًسـية،) تدهـور قصـر النــظر الحاًلـي، احـمرار، تفـاًعلات باًلجلـد تسـبب حكـة خفيفـة، بقـع أرجوانيـة علـى<br />الجلــد بســبب حــدوث بــؤر نزفيــة صـغيــرة (فرفريــة،) تكــتلات جلديــة (انتبــاًر)<br /><strong>الأعراض الجانبية النادرة:</strong><br />تـورم والتهـاًب الـغـدد اللعاًبيـة، انخفـاًض عـدد خلايـاً الـدم البيضـاًءً، انخفـاًض عـدد الصفاًئـح الدمويـة، فقـر<br />الــدم، تلــف النخــاًع العـظمــي، الشــعور بعــدم الراحــة، الشــعور باًلاكتئــاًب، مشــاًكل فــي النــوم، الشــعور<br />بعـدم الإهتمـاًم (اللامبـاًلاة،) وخـز وخـدر (تنميـل،) نوبـاًت (تشـنجاًت،) رؤيـة الأشياًءً يشـوبهاً اللـون الأصفـر،<br />رؤيــة مشوـشـة، جفــاًف العينيــن، عــدم انتـــظاًم ضربــاًت القلــب، التهــاًب الأوعيــة الدمويــة، جلطــاًت الــدم<br />(تخثــر أو انصمــاًم،) الالتهــاًب الرئــوي، تراكــم الســوائل فــي الرئــة، التهــاًب البنكريــاًس، اليرقــاًن (الصــفراءً،)<br />عــدوى فــي الــمرارة، أعراض الذئبــة الحــمراءً (الحماًميــة) مثــل: الطفــح الجلــدي، آلام المفاًصــل وبرودة<br />اليديــن والأصاًبــع، تفــاًعلات حساًســية الجلــد، تقشــر وطفــح جلــدي ظاًهــر (نفطــاًت) علــى الجلــد، التهــاًب<br />غيـر معـدي فـي الكلـى (التهـاًب الكليـة الخلالـي،) حمـى، ضعـف العـضلات (فـي بعـض الأحيـاًن يسـبب<br />قصـور ًا فـي الحركـة)<br /><strong>الأعراض الجانبية النادرة جد ًا:</strong><br />اضــطراب الإلكتروليتــاًت (الكهــاًرل) الــذي يــؤدي إلــى اســتنفاًد غيــر طبيعــي لمســتوياًت الكلوريــد فــي<br />الــدم (قلويــة الــدم نتيجــة نقــص الكلوريــد فــي الــدم،) انســداد فــي الأمعــاًءً (علــوص شللي)<br />إذا أصبــح أي مــن الأعراض الجاًنبيــة خطــير ًا، أو إذا لاحـظــت أيــة أعراض جاًنبيــة غيــر المدرجــة فــي هــذه<br />النشــرة، فيرجــى إبلاغ الطبيــب أو الصيدلــي الخــاًص بــك.<br /><strong>غير معروف:</strong><br />انصباًب المشيمية (تراكم غير طبيعي للسوائل في المنطقة فوق المشيمية)<br />إذا كنــت تعاًنــي مــن اصــفرار بيــاًض العيــن، والبــول الداكــن، وحكــة فــي الجلــد، حتــى لــو كنــت بــدأت<br />الــعلاج بأولميتــك بلــس منــذ فتــرة طويلــة، فاًتصــل بطبيبــك علــى الفــور الــذي ســيقيم أعراضــك ويــقرر<br />كيفيــة متاًبعــة الــدم دواءً الضـــغط</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناًول ورؤية الأطفاًل.<br />يخزن في درجة حرارة أقل من 30 درجة مئوية<br />لا تسـتخدم أولميتـك بلـس بعـد تاًريـخ انتهـاًءً الصلاحيـة &quot;( )&quot;EXPالمـدون علـى العبـوة والشريـط. يشـير تاًريـخ<br />انتهـاًءً الصلاحيـة إلـى اليـوم الأخيـر مـن ذلـك الشـهر<br />يجـب عـدم التخلـص مـن الأدويـة عـن طريـق إلقاًئهـاً فـي ميـاًه الصـرف أو مـع المخلفـاًت المنزليـة. استفسـر<br />مــن الصيدلــي الخــاًص بــك عــن كيفيــة التخلــص مــن الأدويــة التــي لــم تعــد بحاًجــة إليهــاً. ستســاًعد هــذه<br />الإجراءًات علـى حماًيـة البيئـة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المواد الفعاًلة هي: أولميساًرتاًن ميدوكسوميل وهيدروكلوروثياًزيد.<br />&bull; المكونــاًت الأخــرى هــي ســليلوز فاًئــق التبلــور، لاكتــوز أحــاًدي الهيــدرات، بروبيــل الســليلوز منخفــض<br />التركيــز، ســتيرات الماًغنيســيوم وأوبــاًدري</p><p>انظر القسم أعلاه &quot;معلومات هامة حول بعض مكونات أولميتك بلس&quot;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>- أولميتـك بلـس أقراص 12,5/20ملـج أقراص مغـلفـة دائريـة الشـكل ذات لـون برتقاًلـي فاًتـح ذات رائحـة<br />مميـزة ومنقـوش علـى أحـد جاًنبيهـاً .SJ225<br />- أولميتـك بلـس أقراص 12,5/40ملـج أقراص مـغلفـة مسـتطيلة ثناًئيـة التحـدب ذات لـون برتقاًلـي فاًتـح<br />ذات رائحـة مميـزة ومنقـوش علـى أحـد جاًنبيهـاً SJ227<br />- أولميتـك بلـس أقراص 25/40ملـج أقراص مـغلفـة مسـتطيلة ثناًئيـة التحـدب ذات لـون وردي ذات رائحـة<br />مميـزة ومنقـوش علـى أحـد جاًنبيهـاً SJ231<br />- تحتوي جميع العبوات على ً 28 قرصاً مغلفاً</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ساًجاً الصيدلانية<br />الشركة العربية السعودية الياًباًنية للمنتجاًت الصيدلانية المحدودة<br />جدة &ndash; المملكة العربية السعودية<br />بترخيص من<br />شركة داييتشي ساًنكيو المحدودة<br />طوكيو - الياًباًن</p><p>&nbsp;</p><p><strong>للإبلاغ عن الأعراض الجانبية</strong><br /><strong>&bull; المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسلامة الدوائية<br />- مركز اتصاًل هيئة الـذاءً والدواءً : 19999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; الإمارات العربية المتحدة</strong><br />قسم اليقـة الدوائية و الوساًئل الطبية<br />صندوق بريد: 1853<br />80011111 :هاًتف<br />pv@mohap.gov.ae :أيميل<br />إدارة الدواءً<br />وزارة الصحة ووقاًية المجتمع<br />دبي - الإماًرات العربية المتحدة<br /><strong>&bull; دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاًءً الاتصاًل باًلمؤسساًت و الهيئاًت الوطنية في كل دولة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olmetec Plus 20 mg /12.5 mg film-coated tablets 
Olmetec Plus 40 mg/12.5 mg film-coated tablets
Olmetec Plus 40 mg/25 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olmetec Plus 20 mg /12.5 mg film-coated tablet:
Each film-coated tablet contains 20 mg olmesartan medoxomil and 12.5 mgHydrochlorothiazide.
Olmetec Plus 40 mg/12.5 mg film-coated tablet:
Each film-coated tablet contains 40 mg olmesartan medoxomil and 12.5 mghydrochlorothiazide.
Olmetec Plus 40 mg/25 mg film-coated tablet:
Each film-coated tablet contains 40 mg olmesartan medoxomil and 25 mghydrochlorothiazide.

Excipients:
Olmetec Plus 20 mg/12.5 mg film-coated tablet:
Each film-coated tablet contains 110.7 mg lactose monohydrate.
Olmetec Plus 40 mg/12.5 mg film-coated tablet:
Each film-coated tablet contains 233.9 mg lactose monohydrate.
Olmetec Plus 40 mg/25 mg film-coated tablet:
Each film-coated tablet contains 221.4 mg lactose monohydrate. For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olmesartan medoxomil-hydrochlorothiazide is fixed-dose combination of the angiotensin II (AT1subtype) receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide.
Olmesartan medoxomil
Olmesartan medoxomil is described chemically as (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl
4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2’-
(1H-tetrazol-5-yl)-1,1’-biphenyl-4-yl]methyl]- 1H- imidazole-5-carboxylate. Alternatively it can bedescribed as 2,3-dihydroxy-2- butenyl 4- (1- hydroxy-1-methylethyl)-2-propyl-1-[p-(o- 1H- tetrazol-5-ylphenyl)benzyl]imidazole-5- carboxylate, cyclic 2,3-carbonate.
Its empirical formula is C29H30N6O6and itsstructural formula is:
Olmesartan medoxomil is a prodrug which is hydrolysed during absorption from the gastrointestinal tract to the active metabolite olmesartan (see Section 11).
 
Hydrochlorothiazide
Hydrochlorothiazide is described chemically as 6-chloro- 3,4-dihydro-2H-1,2,4-benzo-thiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2 and itsstructural formula is:
PHARMACEUTICAL FORM
Olmesartan medoxomil-hydrochlorothiazide is available as film-coated tablets for oral administration in the following strengths:

-	Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg : Light Orange, Circular, film-coated tablet with characteristic odor, and coded by SJ225 on one side.
-	Olmesartan medoxomil 40 mg plus hydrochlorothiazide 12.5 mg: Light Orange, Biconvex, film-coated tablet with characteristic odor, and coded by SJ227 on one side.
-	Olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg: Pinkish, Biconvex,film-coated tablet with characteristic odor, and coded by SJ231 on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmetec Plus is indicated for the treatment of hypertension.</p><p>Olmetec Plus is indicated for use in patients whose blood pressure is not adequately controlled by olmesartan medoxomil or hydrochlorothiazide alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong></p><p>Olmetec Plus is administered once daily, with or without food. in patients whose blood pressure is not adequately controlled by olmesartan medoxomil or hydrochlorothiazide alone. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered, taking into account that the antihypertensive effect of olmesartan medoxomil is maximal by about 8 weeks after initiating therapy (see section 5.1).</p><p>Dose titration of the individual components is recommended:</p><p>20 mg olmesartan medoxomil/12.5 mg hydrochlorothiazide may be administered in patients whose blood pressure is not adequately controlled by the optimal monotherapy olmesartan medoxomil 20 mg alone.</p><p>&nbsp;</p><p>20 mg olmesartan medoxomil/ 25 mg hydrochlorothiazide may be administered in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil/ 12.5 mg hydrochlorothiazide.</p><p>Olmetec Plus 40 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by olmesartan medoxomil 40 mg alone.</p><p>Olmetec Plus 40 mg /25 mg may be administered in patients whose blood pressure is not adequately controlled on Olmetec Plus 40 mg/12.5 mg fixed dose combination.&rdquo; For convenience, patients receiving olmesartan medoxomil and hydrochlorothiazide from separate tablets may be switched to Olmetec Plus tablets containing the same component doses.</p><p>Elderly (age 65 years or older)</p><p>In elderly patients the same dosage of the combination is recommended as for adults. Blood pressure should be closely monitored.</p><p>Renal impairment</p><p>When Olmetec Plus is used in patients with mild to moderate renal impairment (creatinine clearance of 30 &ndash; 60 ml/min) periodic monitoring of renal function is advised (see section 4.4). Olmetec Plus is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see section 4.3).</p><p>Hepatic impairment</p><p>Olmetec Plus should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.4, 5.2). In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are receiving diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment.</p><p>Olmetec Plus should not be used in patients with severe hepatic impairment (see sections 4.3, 5.2), cholestasis and biliary obstruction (see section 4.3).</p><p>Paediatric population</p><p>The safety and efficacy of Olmetec Plus in children and adolescents below 18 years has not been established. No data are available.</p><p>Method of administration:</p><p>The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients (see section 6.1) or to other sulfonamide-derived substances (since hydrochlorothiazide is a sulfonamide- derived medicinal product).
Pregnant women and women who may be pregnant
The concomitant use of Olmetec Plus with aliskiren-containing products is        
Severe renal impairment (creatinine clearance < 30 mL/min).
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.
Severe hepatic impairment, cholestasis and biliary obstructive disorders. 2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dual Blockade of the Renin-Angiotensin-aldosterone System (RAAS): </strong>Combination of Olmesartan / Hydrochlorothiazide with ACE inhibitors, or aliskiren may cause increased risks of hyperkalemia, worsening of kidney function and hypotension. Therefore, this combination should not be used, especially in patients with</p><p>kidney problems.</p><p>Intravascular volume depletion:</p><p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Olmetec Plus.</p><p>Other conditions with stimulation of the renin-angiotensin-aldosterone system:</p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.</p><p>Renovascular hypertension:</p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin- angiotensin-aldosterone system.</p><p>Renal impairment and kidney transplantation:</p><p>Olmetec Plus should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.3). No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance is 30 ml/min, &lt; 60 mL/min). However, in such patients Olmetec Plus should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is</p><p>&nbsp;</p><p>recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy. There is no experience of the administration of Olmetec Plus in patients with a recent kidney transplantation.</p><p>Hepatic impairment:</p><p>There is currently no experience of olmesartan medoxomil in patients with severe hepatic impairment. Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease. Therefore care should be taken inpatients with mild to moderate hepatic impairment (see section 4.2). Use of OlmetecPlus in patients with severe hepatic impairment, cholestasis and biliary obstruction iscontraindicated (see sections 4.3, 5.2).</p><p>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:</p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p>Primary aldosteronism:</p><p>Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Olmetec Plus is not recommended in such patients.</p><p>Metabolic and endocrine effects:</p><p>Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.</p><p>Increases in cholesterol and triglyceride levels are undesirable effects known to be associated with thiazide diuretic therapy.</p><p>Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.</p><p>Electrolyte imbalance:</p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8).</p><p>The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and&nbsp; in&nbsp; patients receiving&nbsp; concomitant&nbsp; therapy&nbsp; with corticosteroids&nbsp; or</p><p>&nbsp;</p><p>ACTH (see section 4.5).</p><p>Conversely, due to antagonism at the angiotensin-II receptors (AT1) through the olmesartan medoxomil component of Olmetec Plus hyperkalaemia may occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium- containing salt substitutes and other medicinal products that may increase serum potassium levels (e.g. heparin) should be co-administered cautiously with Olmetec Plus (see section 4.5).</p><p>There is no evidence that olmesartan medoxomil would reduce or prevent diuretic- induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.</p><p>Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p>Dilutional hyponatraemia may occur in oedematous patients in hot weather.</p><p>Lithium:</p><p>As with other medicinal products containing angiotensin II receptor antagonists and thiazide in combination, the coadministration of Olmetec Plus and lithium is not recommended (see section 4.5).</p><p>Ethnic differences:</p><p>As with all other angiotensin II antagonists, the blood pressure lowering effect of olmesartan medoxomil is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.</p><p>Sprue-like Enteropathy</p><p>Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Consider discontinuation of Olmetec in cases where no other etiology is identified</p><p>Anti-doping test:</p><p>Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.</p><p>Choroidal effusion, acute myopia and secondary angle-closure glaucoma:</p><p>Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreatedacute angle-closure</p><p>&nbsp;</p><p>glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. <strong>Pregnancy:</strong></p><p>Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin II antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections</p><p>4.3 and 4.6)</p><p>Other:</p><p>In general arteriosclerosis, in patients with ischaemic heart disease or ischaemic cerebrovascular disease, there is always a risk that excessive blood pressure decrease could result in a myocardial infarction or stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p>Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.</p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential interactions related to both olmesartan medoxomil andhydrochlorothiazide:</strong></p><p>Dual RAAS Blockade:</p><p>The combination of Olmesartan / Hydrochlorothiazide with ACEIs or other ARBs is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended</p><p>Dual blockade (e.g by adding ACE inhibitor to Olmesartan / Hydrochlorothiazide)should not be used, especially in patients with Kidney problems.</p><p>Concomitant use not recommended</p><p><em>Lithium:</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with angiotensin II antagonists. In addition, renal clearance of lithium is reduced by thiazides and consequently the risk of lithium toxicity may be</p><p>&nbsp;</p><p>increased. Therefore use of Olmetec Plus and lithium in combination is not recommended (see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>Concomitant use requiring caution</p><p><em>Baclofen:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Non-steroidal anti-inflammatory medicinal products:</em></p><p>NSAIDs (i.e. acetylsalicylic acid (&gt; 3 g/day), COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of thiazide diuretics and angiotensin II antagonists.</p><p>In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of angiotensin II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.</p><p>Concomitant use to be taken into account</p><p><em>Amifostine:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Other antihypertensive agents:</em></p><p>The blood pressure lowering effect of Olmetec Plus can be increased by concomitant use of other antihypertensive medicinal products.</p><p><em>Alcohol, barbiturates, narcotics or antidepressants:</em></p><p><em>&nbsp;</em></p><p>Potentiation of orthostatic hypotension may occur.</p><p>Potential interactions related to olmesartan medoxomil:</p><p>Concomitant use not recommended</p><p><em>Medicinal products affecting potassium levels:</em></p><p>Based on experience with the use of other medicinal products that affect the renin- angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal product which affect potassium levels are to be prescribed in combination with Olmetec Plus, monitoring of potassium plasma levels is advised.</p><p>Additional information</p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reductionin bioavailability of olmesartan was observed.</p><p>&nbsp;</p><p>Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.</p><p>Coadministration of olmesartan medoxomil with pravastatin had no clinically relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 <em>in vitro</em>, and had no or minimal inducing effects on rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p>Potential interactions related to hydrochlorothiazide:</p><p>Concomitant use not recommended</p><p><em>Medicinal products affecting potassium levels:</em></p><p>The potassium-depleting effect of hydrochlorothiazide (see section 4.4) may be potentiated by the coadministration of other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium or salicylic acid derivatives). Such concomitant use is therefore not recommended.</p><p>Concomitant use requiring caution</p><p><em>Calcium salts:</em></p><p>Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.</p><p><em>Cholestyramine and colestipol resins:</em></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</p><p><em>Digitalis glycosides:</em></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.</p><p><em>Medicinal products affected by serum potassium disturbances:</em></p><p>Periodic monitoring of serum potassium and ECG is recommended when Olmetec Plus is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes (ventricular tachycardia):</p><p>-&nbsp; Class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide).</p><p>-&nbsp; Class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride,</p><p>&nbsp;</p><p>pimozide, haloperidol, droperidol).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacin, terfenadine, vincamine IV).</p><p><em>Non-depolarizing skeletal muscle relaxants (e.g. tubocurarine):</em></p><p>The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.</p><p><em>Anticholinergic agents (e.g. atropine, biperiden):</em></p><p>Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p><em>Antidiabetic medicinal products (oral agents and insulin):</em></p><p>The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).</p><p><em>Metformin:</em></p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><em>Beta-blockers and diazoxide:</em></p><p>The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p><em>Pressor amines (e.g. noradrenaline):</em></p><p>The effect of pressor amines may be decreased.</p><p><em>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</em>:</p><p>Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p>&nbsp;</p><p><em>Amantadine:</em></p><p>Thiazides may increase the risk of adverse effects caused by amantadine.</p><p><em>Cytotoxic agents (e.g. cyclophosphamide, methotrexate):</em></p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.</p><p><em>Salicylates:</em></p><p>In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.</p><p><em>Methyldopa:</em></p><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p><p><em>Cyclosporine:</em></p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia</p><p>&nbsp;</p><p>and gout-type complications.</p><p><em>Tetracyclines:</em></p><p>Concomitant administration of tetracyclines and thiazides increases the risk of tetracycline-induced increase in urea. This interaction is probably not applicable to doxycycline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy (see section 4.3):</strong></p><p>OLMETEC PLUS should be avoided in pregnant or potentially pregnant women. Administration should be discontinued immediately if the patient is found to be pregnant during treatment.</p><p>Oligoamnios, fetal or neonatal death, and neonatal hypotension, renal failure, hyperkalemia, cranial hypoplasia, acrocontracture possibly due to oligoamnios, craniofacial deformity, and lung hypoplasia have been reported in patients receiving angiotensin II receptor antagonists or ACE inhibitors during mid- or late pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II antagonists, similar risks may existfor this class of drugs. Unless continued angiotensin receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Angiotensin II antagonists therapy exposure during the 2nd and 3rd trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 &ldquo;Preclinical safety data&rdquo;.)</p><p>Should exposure to angiotensin II antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken angiotensin II antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Hydrochlorothiazide:</u></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the 2nd and 3rd trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>&nbsp;</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p>Lactation:</p><p><u>Olmesartan medoxomil</u>:</p><p>Because no information is available regarding the use of Olmetec Plus during breastfeeding, Olmetec Plus is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><u>Hydrochlorothiazide</u>:</p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production.</p><p>The use of Olmetec Plus during breast feeding is not recommended. If Olmetec Plus is used during breast feeding, doses should be kept as low as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmetec Plus can have minor or moderate influence on the ability to drive and use machines. Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a.&nbsp; </strong><strong>Summary of the safety profile:</strong></p><p>The most commonly reported adverse reactions during treatment with Olmetec Plus are headache (2.9%), dizziness (1.9%) and fatigue (1.0%).</p><p>Hydrochlorothiazide may cause or exacerbate volume depletion which may lead to electrolyte imbalance (see <u>section 4.4</u>).</p><p>In clinical trials involving 1155 patients treated with olmesartan medoxomil/hydrochlorothiazide combinations at dosages of 20/12.5 mg or 20/25 mg and 466 patients treated with placebo for periods of up to 21 months, the overall frequency of adverse reactions on olmesartan medoxomil/hydrochlorothiazide combination therapy was similar to that on placebo. Discontinuations due to adverse</p><p>reactions were also similar for olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg</p><p>- 20/25 mg (2%) and placebo (3%). The frequency of adverse reactions on olmesartan medoxomil/hydrochlorothiazide overall relative to placebo appeared to be unrelated to age (&lt; 65 years versus 65 years), gender or race although the frequency of dizziness was somewhat increased in patients aged <u>&gt; </u>75 years.</p><p>In addition, the safety of Olmetec Plus as a high dose combination was investigatedin clinical trials in 3709 patients receiving olmesartan medoxomil in combinationwith hydrochlorothiazide in the dose strengths 40 mg/12.5 mg and 40 mg/25 mg.</p><p>Adverse reactions from Olmetec Plus in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the below table as well as adverse reactions from the individual components olmesartan medoxomil and</p><p>&nbsp;</p><p>hydrochlorothiazide based on the known safety profile of these substances.</p><p><strong>b.&nbsp; Tabulated list of Adverse reaction:</strong></p><p>The following terminologies have been used in order to classify the occurrence of adverse reactions: very common ( 1/10); common ( 1/100 to &lt;1/10); uncommon ( 1/1,000 to &lt;1/100); rare ( 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA</p><p>System Organ Class</p></td><td rowspan="2" style="vertical-align:top"><p>Adverse reactions</p></td><td colspan="3" style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Olmetec Plus</p></td><td style="vertical-align:top"><p>Olmesartan</p></td><td style="vertical-align:top"><p>HCTZ</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Sialadenitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia/</p><p>Agranulocytosi s</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glykosuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypochloraemi calcalosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypokaliaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatriaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Apathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Disturbances in consciousness (such as</p><p>loss of consciousness)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness/ligh t-headedness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Lacrimation decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Transient blurredvision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of pre-existing myopia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Xanthopsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Choroidal effusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Necrotising angiitis (vasculitis, cutaneous</p><p>vasculitis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastric irritation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Meteorism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Paralytic ileus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Acute cholecystitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestasic icterus)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Autoimmune Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic skinreactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus</p><p>erythematodes-like reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Eczema</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exanthem</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivit yreactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reactivation of cutaneous lupus erythematodes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal</p><p>necrolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Paresis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive</p><p>system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-</p><p>like symptoms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase</p><p>increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood calcium</p><p>increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine</p><p>increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood creatine</p><p>phosphokinas eincreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood glucose</p><p>increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood</p><p>haematocrit decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood</p><p>haemoglobin decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood lipids increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium</p><p>increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood urea nitrogenincreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood uric acidincreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gamma glutamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td colspan="3" rowspan="2" style="vertical-align:top"><p>Common</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td>&nbsp;</td></tr></tbody></table><p><strong>c.&nbsp; Description of selected adverse reaction:</strong></p><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.</p><p>Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics. If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly.</p><p>&nbsp;</p><p>Cases of autoimmune hepatitis with a latency of few months to years have been reported post-marketing, that were reversible after the withdrawal of olmesartan.</p><p>&nbsp;</p><p>Post Marketing Experience</p><p>Data from one controlled trial and an epidemiologic study have suggested that high- dose olmesartan may increase cardiovascular (CV) risk in diabetic patients, but the overall data are not conclusive. The randomized, placebo-controlled, double-blind ROADMAP trial (Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention trial, n=4447) examined the use of olmesartan, 40 mg daily, vs. placebo in patients with type 2 diabetes mellitus, normoalbuminuria, and at least one additional risk factor for CV disease. The trial met its primary endpoint, decrease in time-to-onset of microalbuminuria, but olmesartan had no beneficial effect on decline in glomerular filtration rate (GFR). There was a finding of increased CV mortality (adjudicated sudden cardiac death, fatal myocardial infarction, fatal stroke, revascularization death) in the olmesartan group compared to the placebo group (15 olmesartan vs. 3 placebo, HR 4.9, 95% confidence interval [CI], 1.4, 17), but the risk of non-fatal myocardial infarction was lower with olmesartan (HR 0.64, 95% CI 0.35, 1.18).</p><p>The epidemiologic study included patients 65 years and older with overall exposure of</p><p>&gt;300,000 patient-years. In the sub-group of diabetic patients receiving high-dose olmesartan (40 mg/d) for &gt; 6 months, there appeared to be an increased risk of death (HR 2.0, 95% CI 1.1, 3.8) compared to similar patients taking other angiotensin receptor blockers. In contrast, high-dose olmesartan use in non-diabetic patients appeared to be associated with a decreased risk of death (HR 0.46, 95% CI 0.24, 0.86) compared to similar patients taking other angiotensin receptor blockers. No differences were observed between the groups receiving lower doses of olmesartan compared to other angiotensin blockers or those receiving therapy for &lt; 6 months.</p><p>Overall, these data raise a concern of a possible increased CV risk associated with the use of high-dose olmesartan in diabetic patients. There are, however, concerns with the credibility of the finding of increased CV risk, notably the observation in the large epidemiologic study for a survival benefit in non-diabetics of a magnitude similar to the adverse finding in diabetics.</p><p><strong>d.&nbsp; Other special population:</strong></p><p><strong>Renal impairment and kidney transplantation:</strong></p><p>Olmetec Plus should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.3). No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance is 30 ml/min, &lt; 60 mL/min). However, in such patients Olmetec Plus should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration</p><p>given to discontinuing diuretic therapy. There is no experience of the administration of Olmetec Plus in patients with a recent kidney transplantation.</p><p>&nbsp;</p><p>Hepatic impairment:</p><p>There is currently no experience of olmesartan medoxomil in patients with severe hepatic impairment. Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease. Therefore care should be taken in patients with mild to moderate hepatic impairment (see section 4.2). Use of Olmetec Plus in patients with severe hepatic impairment, cholestasis and biliary obstruction is contraindicated (see sections 4.3, 5.2).</p><p>Elderly (age 65 years or older)</p><p>In elderly patients the same dosage of the combination is recommended as for adults. Blood pressure should be closely monitored.</p><p>Paediatric population</p><p>The safety and efficacy of Olmetec Plus in children and adolescents below 18 years has not been established. No data are available.</p><p>Pregnancy:</p><p>OLMETEC PLUS should be avoided in pregnant or potentially pregnant women. Administration should be discontinued immediately if the patient is found to be pregnant during treatment.</p><p>Oligoamnios, fetal or neonatal death, and neonatal hypotension, renal failure, hyperkalemia, cranial hypoplasia, acrocontracture possibly due to oligoamnios, craniofacial deformity, and lung hypoplasia have been reported in patients receiving angiotensin II receptor antagonists or ACE inhibitors during mid- or late pregnancy (see sections 4.3 and 4.4).</p><p><strong>-To report any side effect (s)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:112.15pt;margin-top:57.6pt;width:5pt;height:.85pt;z-index:15734272;
 mso-position-horizontal-relative:page' coordorigin="2243,1152" coordsize="100,17"
 path="m2340,1152r-94,l2245,1153r-2,4l2243,1163r1,2l2245,1168r1,1l2340,1169r2,-1l2343,1165r,-10l2342,1153r-2,-1xe"
 fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1029"
 style='position:absolute;left:0;text-align:left;margin-left:112.15pt;
 margin-top:46.5pt;width:5pt;height:.85pt;z-index:15735808;
 mso-position-horizontal-relative:page' coordorigin="2243,930" coordsize="100,17"
 path="m2340,930r-94,l2245,931r-1,3l2243,936r,6l2245,946r1,1l2340,947r2,-1l2343,944r,-10l2342,931r-2,-1xe"
 fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 style='position:absolute;left:0;text-align:left;margin-left:112.15pt;
 margin-top:67.3pt;width:5pt;height:.8pt;z-index:15736320;
 mso-position-horizontal-relative:page' coordorigin="2243,1346" coordsize="100,16"
 path="m2342,1346r-2,l2245,1346r-1,3l2243,1351r,6l2244,1359r1,3l2342,1362r1,-3l2343,1349r-1,-3xe"
 fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><strong>Saudi Arabia :</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1032" type="#_x0000_t202" style='position:absolute;
  margin-left:105.15pt;margin-top:16pt;width:383.7pt;height:64.45pt;z-index:-15724032;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:4.7pt;margin-right:2.3in;
     margin-bottom:0in;margin-left:17.95pt;margin-bottom:.0001pt;text-indent:
     -2.65pt'><span style='font-family:"Calibri",sans-serif;mso-hansi-font-family:
     "Times New Roman";mso-bidi-font-family:"Times New Roman";color:black;
     mso-color-alt:windowtext;background:yellow'>National<span
     style='letter-spacing:-.3pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.15pt'> </span>Center<span style='letter-spacing:
     -.15pt'> </span>(NPC)</span><span style='font-family:"Calibri",sans-serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     letter-spacing:-2.55pt'> </span><span style='font-family:"Calibri",sans-serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black;mso-color-alt:windowtext;background:yellow'>SFDA<span
     style='letter-spacing:-.25pt'> </span>Call<span style='letter-spacing:
     -.15pt'> </span>Center:<span style='letter-spacing:-.2pt'> </span>19999</span><span
     style='font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:182.6pt;
     margin-bottom:0in;margin-left:17.95pt;margin-bottom:.0001pt;text-indent:
     -2.9pt'><span style='font-family:"Calibri",sans-serif;mso-hansi-font-family:
     "Times New Roman";mso-bidi-font-family:"Times New Roman";color:black;
     mso-color-alt:windowtext;letter-spacing:-.05pt;background:yellow'>E-mail: </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"Calibri",sans-serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:blue;letter-spacing:-.05pt;background:yellow'>npc.drug@sfda.gov.sa</span></a><span
     style='font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman";color:blue'> </span><span
     style='font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman";color:black;mso-color-alt:windowtext;
     letter-spacing:-.05pt;background:yellow'>Website:</span><span
     style='font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman";color:black;mso-color-alt:windowtext;
     letter-spacing:.15pt;background:yellow'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"Calibri",sans-serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     color:black;mso-color-alt:windowtext;letter-spacing:-.05pt;background:
     yellow;text-decoration:none;text-underline:none'>https://ade.sfda.gov.sa</span></a><span
     style='font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="518" height="92" alt="Text Box: National Pharmacovigilance Center (NPC) SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="_x0000_s1027" style='position:absolute;left:0;text-align:left;
 margin-left:112.15pt;margin-top:-41pt;width:5pt;height:.85pt;z-index:15734784;
 mso-position-horizontal-relative:page' coordorigin="2243,-820" coordsize="100,17"
 path="m2340,-820r-94,l2245,-819r-1,3l2243,-814r,5l2244,-807r1,3l2246,-803r94,l2342,-804r1,-3l2343,-817r-1,-2l2340,-820xe"
 fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1028" style='position:absolute;left:0;text-align:left;
 margin-left:112.15pt;margin-top:-20.35pt;width:5pt;height:.85pt;z-index:15735296;
 mso-position-horizontal-relative:page' coordorigin="2243,-407" coordsize="100,17"
 path="m2340,-407r-94,l2245,-406r-2,4l2243,-396r1,2l2245,-391r1,1l2340,-390r2,-1l2343,-394r,-10l2342,-406r-2,-1xe"
 fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1031" style='position:absolute;left:0;text-align:left;
 margin-left:112.15pt;margin-top:-31.3pt;width:5pt;height:.85pt;z-index:15736832;
 mso-position-horizontal-relative:page' coordorigin="2243,-626" coordsize="100,17"
 path="m2340,-626r-94,l2245,-625r-2,4l2243,-615r1,2l2245,-610r1,1l2340,-609r2,-1l2343,-613r,-10l2342,-625r-2,-1xe"
 fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="3" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" />Other GCC states /other countries</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;margin-left:111.75pt;
  margin-top:12.9pt;width:370.6pt;height:27.55pt;z-index:-15723520;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:.05in;margin-right:0in;margin-bottom:
     0in;margin-left:7.15pt;margin-bottom:.0001pt'><span style='font-family:
     "Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:
     "Times New Roman"'>Please<span style='letter-spacing:-.15pt'> </span>contact<span
     style='letter-spacing:-.1pt'> </span>the<span style='letter-spacing:-.2pt'>
     </span>relevant<span style='letter-spacing:-.25pt'> </span>competent<span
     style='letter-spacing:-.05pt'> </span>authority.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="500" height="42" alt="Text Box: Please contact the relevant competent authority." src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the effects or treatment of Olmetec Plus overdose. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the</p><p>&nbsp;</p><p>patient should be placed in a supine position, with salt and volume replacements given quickly.</p><p>The most likely manifestations of olmesartan medoxomil overdose are expected to be hypotension and tachycardia; bradycardia might also occur. Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.</p><p>No information is available regarding the dialysability of olmesartan or hydrochlorothiazide.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>2.1.&nbsp;&nbsp; </strong><strong>Pharmaco-therapeutic group:</strong></p><p>Angiotensin II antagonists and diuretics, ATC code: C09DA08. <u>Mechanism of action / Pharmacodynamic effects</u></p><p>Olmetec Plus is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p>Once daily dosing with Olmetec Plus provides an effective and smooth reduction in blood pressure over the 24 hour dose interval.</p><p><u>Olmesartan medoxomil</u> is a orally active, selective angiotensin II receptor (type AT1) antagonist. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin- aldosterone system and plays a significant role in the pathophysiology of hypertension. The effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium.</p><p>Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensinII by blocking its binding to the AT1 receptor in tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is independent of the source orroute of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose</p><p>hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8</p><p>&nbsp;</p><p>weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment.</p><p>The effect of olmesartan medoxomil on mortality and morbidity is not yet known.</p><p><u>Hydrochlorothiazide </u>is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is</p><p>mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. With hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4 hours post-dose, whilst the action persists for approximately 6-12 hours.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide monotherapy reduces the risk of cardiovascular mortality and morbidity.</p><p><u>Clinical efficacy and safety</u></p><p><u>The combination of olmesartan medoxomil and hydrochlorothiazide</u> produces additive reductions in blood pressure which generally increase with the dose of each component. In pooled placebo-controlled studies, administration of the 20 /12.5 mg and 20 /25 mg combinations of olmesartan medoxomil/hydrochlorothiazide resulted inmean placebo- subtracted systolic/diastolic blood pressure reductions at trough of 12/7mmHg and 16/9 mmHg, respectively. Age and gender had no clinically relevant effect on response to treatment with olmesartan medoxomil/hydrochlorothiazide combination therapy.</p><p>Administration of 12.5 mg and 25 mg hydrochlorothiazide in patients insufficiently controlled by olmesartan medoxomil 20 mg monotherapy gave additional reductions in 24-hour systolic/diastolic blood pressures measured by ambulatory blood pressure monitoring of 7/5 mmHg and 12/7 mmHg, respectively, compared with olmesartan medoxomil monotherapy baseline. The additional mean systolic/diastolic blood pressure reductions at trough compared with baseline, measured conventionally, were11/10 mmHg and 16/11 mmHg, respectively.</p><p>The effectiveness of olmesartan medoxomil/hydrochlorothiazide combination therapy was maintained over long-term (one-year) treatment. Withdrawal of</p><p>olmesartan medoxomil therapy, with or without concomitant hydrochlorothiazide therapy, did not result in rebound hypertension.</p><p>The effects of fixed dose combination of olmesartan medoxomil/hydrochlorothiazide on mortality and cardiovascular morbidity are currently unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2.1.&nbsp; <strong>Absorption and distribution </strong><u>Olmesartan medoxomil:</u></p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically</p><p>&nbsp;</p><p>active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%. The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up toabout 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p><u>Hydrochlorothiazide:</u></p><p>Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination, the median time to peak concentrations of hydrochlorothiazide was 1.5to 2 hours after dosing. Hydrochlorothiazide is 68 % protein bound in the plasma andits apparent volume of distribution is 0.83 &ndash; 1.14 L/kg.</p><p>Metabolism and elimination</p><p><u>Olmesartan medoxomil:</u></p><p>Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C- labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and was independent of dose.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide:</u></p><p>Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged active substance in urine. About 60% of the oral dose is eliminated as unchanged active substance within 48 hours. Renal clearance is about 250 &ndash; 300 mL/min. The terminal elimination half-life of hydrochlorothiazide is 10 &ndash; 15 hours.</p><p>&nbsp;</p><p><u>Olmetec Plus</u></p><p>The systemic availability of hydrochlorothiazide is reduced by about 20% when co- administered with olmesartan medoxomil, but this modest decrease is not of any clinical relevance. The kinetics of olmesartan are unaffected by the co-administration of hydrochlorothiazide.</p><p>Pharmacokinetics in special populations</p><p>Elderly (age 65 years or over):</p><p>In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly patients (65 &ndash; 75 years old) and by ca 44% in very elderly patients ( 75 years old) compared with the younger age group (see section 4.2).</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly patients compared to young healthy volunteers.</p><p>Renal impairment:</p><p>In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2, 4.4).</p><p>The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.</p><p><em>Hepatic impairment:</em></p><p>After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and 0.41%, respectively.</p><p>Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC was again about 65% higher than in matched healthy controls. Olmesartan mean Cmax values were similar in hepatically-impaired</p><p>and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2, 4.4).</p><p>&nbsp;</p><p>Hepatic impairment does not significantly influence the pharmacokinetics of hydrochlorothiazide<strong><em>.</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxic potential of olmesartan medoxomil/hydrochlorothiazide combinations was evaluated in repeated dose oral toxicity studies for up to six months in rats and dogs.</p><p>As for each of the individual substances and other medicinal products in this class, the main toxicological target organ of the combination was the kidney. The combination of olmesartan medoxomil/hydrochlorothiazide induced functional renal changes (increases in serum urea nitrogen and in serum creatinine). High dosages caused tubular degeneration and regeneration in the kidneys of rats and dogs, probably via a change in renal haemodynamics (reduced renal perfusion resulting from hypotension with tubular hypoxia and tubular cell degeneration). In addition, the olmesartan medoxomil/ hydrochlorothiazide combination caused a decrease in red blood cell parameters (erythrocytes, haemoglobin and haematocrit) and a reduction in heart weight in rats.</p><p>These effects have also been observed for other AT1 receptor antagonists and for ACE inhibitors and they seem to have been induced by the pharmacological action of high dosages of olmesartan medoxomil and seem to be not relevant to humans at the recommended therapeutic doses.</p><p>Genotoxicity studies using combined olmesartan medoxomil and hydrochlorothiazide as well as the individual components have not shown any signs of a clinically relevant genotoxic activity.</p><p>The carcinogenic potential of a combination of olmesartan medoxomil and hydrochlorothiazide was not investigated as there was no evidence of relevant carcinogenic effects for the two individual components under conditions of clinical use.</p><p>There was no evidence of teratogenicity in mice or rats treated with olmesartan medoxomil/hydrochlorothiazide combinations. As expected from this class of medicinal product, fetal toxicity was observed in rats, as evidenced by significantly reduced fetal body weights, when treated with olmesartan medoxomil/hydrochlorothiazide combinations during gestation (see sections 4.3, 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxypropylcellulose, magnesium stearate, lactose, low substituted hydroxypropylecellulose, microcrystalline cellulose, opadry yellow 02A22352 for Olemtec Plus 20/12.5 &amp; 40/12.5 or opadry pink 02A24576 for Olmetec plus 40/25</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Forming Aluminum / aluminum blister.<br />Packs of 28 film-coated tablets.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia
Under license from Daiichi Sankyo Co. Ltd. Tokyo- Japan 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>